Cognito Therapeutics

United States
Primghar, Iowa, United States, 02138

Company profile

Cognito Therapeutics company profile

Cognito Therapeutics is a clinical-stage neurotechnology business focused on creating disease-modifying pharmaceutical methods for the treatment of neurodegenerative illnesses. Li-Huei Tsai and Ed Boyden, MIT Professors, and scientific founders, created its non-invasive neuromodulation platform. The Company's primary therapy is now being studied in a pivotal study for Alzheimer's Disease and has been designated as a Breakthrough Device by the FDA.

Business identity

Contact email
[email protected]
Phone number
857-201-5088
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2016-01-01, Year

Headquarters

Postal code
02138
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
3
Total equity funding
$216.8M
Last funding
Series B / $35M / 2024-01-29
Last equity funding
Series B / $35M
Investors
7
Lead investors
1
Founders
1
Articles
77

Founders and investors

Founders

Li-Huei Tsai

Lead investors

FoundersX Ventures

Investors

Alzheimer's Drug Discovery FoundationFoundersX VenturesIAG Capital PartnersMorningsideOpAmp Capital